Focus Partners Advisor Solutions’s BioMarin Pharmaceuticals BMRN Stock Holding History

Focus Partners Advisor Solutions’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$624K	Sell	10,899 -12,431	-53%	-$681K	0.01%	726
2026 Q1	$1.32M	Buy	23,330 +6,018	+35%	+$351K	0.01%	475
2025 Q4	$1.03M	Sell	17,312 -1,300	-7%	-$70.8K	0.01%	490
2025 Q3	$993K	Buy	18,612 +7,752	+71%	+$443K	0.01%	526
2025 Q2	$597K	Sell	10,860 -1,128	-9%	-$66.4K	0.01%	619
2025 Q1	$847K	Buy	+11,988	New	+$807K	0.01%	425

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Focus Partners Advisor Solutions's BMRN Position: Q2 2026 in Review

Focus Partners Advisor Solutions reduced its BioMarin Pharmaceuticals (BMRN) stake by 53% in Q2 2026, selling an estimated $681K and leaving 10,899 shares worth $624K. The position accounts for 0.01% of the portfolio, ranked #726.

Focus Partners Advisor Solutions first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.32M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Focus Partners Advisor Solutions held 10,899 shares of BioMarin Pharmaceuticals worth $624K as of Q2 2026.
Focus Partners Advisor Solutions sold 12,431 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $681K.
BioMarin Pharmaceuticals made up 0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #726 holding.
Focus Partners Advisor Solutions first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Focus Partners Advisor Solutions's BioMarin Pharmaceuticals position peaked at $1.32M in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.